B.B.

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of B.B.

Quick Facts

Property Description
Active Ingredient Clindamycin Phosphate
Form Topical Solution, Gel, Lotion; Capsules; Injectable Solution
Pharmacological Class Lincosamide Antibiotic / Antimicrobial Agent
General Purpose Managing susceptible bacterial infections
Origin Semi-synthetic derivative

What Type of Medicine is B.B.? (Classification and Origin)

B.B. is an antimicrobial agent belonging to the Lincosamide antibiotic class, utilized for managing certain bacterial infections. The active component, Clindamycin, is a semi-synthetic derivative of the naturally occurring compound Lincomycin. This classification is characterized by a specific spectrum of activity against key Gram-positive aerobic bacteria and a wide range of anaerobic bacteria. The overarching purpose of this agent is to control and resolve these specific microbial threats by limiting the pathogen's ability to grow and multiply.


What is the Active Ingredient in B.B. and How is it Used? (Composition and Forms)

The single active ingredient in this medication is Clindamycin Phosphate. This is a prodrug that is activated within the body or on the skin to release the therapeutically active agent, Clindamycin. This medication is used in managing bacterial infections that affect the skin, such as those associated with acne. The specific phosphate ester composition enhances the drug's solubility, allowing it to be formulated into clear topical solutions and gels, often utilizing a hydroalcoholic base. The preparation is a prescription-only medicine, available for the topical route of administration for skin applications or through systemic routes as injectable solutions or oral capsules.


How Does Clindamycin Work to Fight Bacteria? (General Action and Purpose)

The fundamental mechanism of action of Clindamycin is as a protein synthesis inhibitor. The active drug moiety targets the bacterial cell's internal machinery by binding to the 50S ribosomal subunit, which prevents the formation of necessary protein chains. This action results primarily in a bacteriostatic effect, meaning it inhibits the microbial population from expanding. This provides the clinical basis for its use: to reduce the microbial burden and assist the body in overcoming the established bacterial infection.

Regulatory References

  1. National Institutes of Health
  2. NIH MedlinePlus

What side effects are possible with B.B.?

Bupropion (B.B.) is generally well-tolerated, but like all medications, it can cause side effects. Patients should discuss their full medical history with a healthcare provider, especially conditions such as a history of seizures, eating disorders, or bipolar disorder, as these may increase the risk of certain adverse effects.


Common Side Effects

Common side effects, which may occur in 10% or more of patients, often decrease after the initial weeks of therapy. These include:

  • Dry mouth
  • Nausea
  • Insomnia (difficulty sleeping)
  • Headache
  • Dizziness
  • Constipation
  • Tremor (shaking)

Serious Safety Information and Warnings

Patients taking B.B. should be monitored for serious but less common adverse events and instructed to seek immediate medical attention if they occur. The risk of these events may be dose-dependent.

Serious Side Effect Key Symptoms Requiring Immediate Attention
Seizures Confusion, loss of consciousness, uncontrolled jerking movements.
Neuropsychiatric Changes Worsening depression, suicidal thoughts or behavior, agitation, hostility, anxiety, or mania (signaled by increased energy, racing thoughts, or reckless behavior).
Severe Allergic Reactions Rash, hives, swelling of the face, lips, tongue, or throat, fever, difficulty breathing.
Hypertension Significant increase in blood pressure (often monitored by a healthcare provider).
Angle-Closure Glaucoma Eye pain, changes in vision, swelling or redness in or around the eye.

It is essential to avoid consuming alcohol while taking Bupropion, as this can increase the risk of seizures and other central nervous system side effects. The medication can cause false-positive results on some urine drug screening tests for amphetamines.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the B.B. overdose profile based on documented manifestations and mandated emergency actions. Overexposure to Clindamycin is primarily associated with an increased incidence of gastrointestinal side effects, a presentation noted at high oral dose levels.


Documented Acute Outcomes and Emergency Actions

Classification Regulatory Statement
Severe Acute Outcomes Life-threatening events, including Cardiopulmonary arrest and hypotension, have been reported following too rapid intravenous administration (IV) of the injectable solution, an acute, high-concentration exposure event.
Immediate Action Mandated Seek immediate medical attention or contact a Poison Control center immediately upon suspicion of overdosage.
Urgent Medical Help Call 911 (emergency services) if the individual has collapsed, is experiencing trouble breathing, or has a seizure, as these symptoms require immediate hospital monitoring.

Supportive Management and Constraints

In the event of an overdose, therapy should be discontinued. Management is strictly symptomatic and supportive. Regulatory information specifies that no specific antidote is known for Clindamycin overdosage. Due to the drug’s pharmacological properties, procedures such as hemodialysis are not effective at removing it from the blood. Monitoring and supportive care are required to manage the clinical state, particularly following acute, high-concentration exposure.

Therapeutic Uses of B.B.

What B.B. Treats: Main Uses and Benefits

The therapeutic utility of Clindamycin (B.B.) is focused on managing underlying susceptible bacterial infections across specific clinical domains. Its therapeutic scope includes the management of serious infections caused by susceptible organisms.

This medication is commonly used to help with conditions presenting with systemic or localized discomfort, including septicemia, intra-abdominal infections, severe lower respiratory infections, skin and soft tissue infections like cellulitis and abscesses, inflammatory acne lesions, osteomyelitis, and certain dental infections. It supports the patient by addressing infections that cause symptoms related to inflammatory or irritative states.

It is frequently applied in clinical settings that involve acute or unstable symptom patterns, especially when susceptible bacteria that thrive in low-oxygen environments (anaerobes) are present, or when patients have a documented hypersensitivity or allergy to penicillin-class antibiotics. The availability of this agent supports patients during difficult episodes by easing distress and may help maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Support for Symptomatic Discomfort
Symptom Focus Systemic manifestations like fever and localized symptoms such as inflammation and purulence.
Primary Benefit Contributes to easing the overall symptom load during acute or deep-seated infectious episodes.
Use Context Applied in scenarios where additional management of discomfort from susceptible bacterial infection is required.

Eligibility and Restrictions for Use

Who can and cannot use B.B.?

Eligibility for B.B. (Clindamycin) is strictly defined by regulatory documents based on patient population, history of hypersensitivity, and pre-existing conditions.

Contraindicated Populations (Must Not Use)

  • Hypersensitivity: Individuals with a known allergy to Clindamycin, Lincomycin, or any of the product's excipients are contraindicated.
  • Nonbacterial Infections: The medicine is not for patients with nonbacterial illnesses, such as most upper respiratory tract infections, due to its antimicrobial classification.
  • Meningitis: The medicine must not be used to treat meningitis.
  • Neonates: Multi-dose injectable formulations containing Benzyl Alcohol are contraindicated in premature infants and neonates.

Population Restrictions and Limitations

  • Gastrointestinal Disease: Use is restricted and must be approached with caution in patients with a history of colitis or other severe gastrointestinal disease.
  • Organ Function: Caution is required for patients with markedly reduced hepatic or renal function, and regulatory documents suggest monitoring may be necessary during prolonged therapy for severe impairment.
  • Pregnancy & Lactation: Use is not recommended for nursing mothers due to excretion into human milk. During the first trimester of pregnancy, use is only permitted if clearly needed, due to limited data.
  • Age Limitations: The safety and effectiveness of topical formulations have not been established for children under 12 years of age. Systemic use is established only in children older than one month.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific patterns of interaction for Clindamycin, the active agent in B.B., across several drug classes and substances. These interactions are categorized based on their mechanism and the required restrictions for co-administration.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Agent Category Regulatory Outcome
Metabolic (PK) Strong CYP3A4/3A5 Inhibitors May reduce Clindamycin clearance, requiring monitoring for potential adverse reactions.
Metabolic (PK) Strong CYP3A4/3A5 Inducers (e.g., Rifampicin) May increase Clindamycin clearance, requiring monitoring for potential loss of effectiveness.
Pharmacodynamic Neuromuscular Blocking Agents Clindamycin's intrinsic neuromuscular blocking properties may enhance the action of these agents.
Pharmacodynamic Vitamin K Antagonists (e.g., Warfarin) Associated with reports of increased coagulation tests (PT/INR) and/or bleeding; frequent monitoring of coagulation tests is required.

Administration Restrictions and Incompatibilities

Co-administration with Macrolide Antibacterial Agents (e.g., Erythromycin) is not recommended due to in vitro evidence of antagonism and the potential for clinical significance. Furthermore, the intravenous Clindamycin Phosphate solution is physically incompatible with several agents, including Ampicillin sodium and Magnesium sulfate, and must not be administered in the same IV fluid. For the oral formulation, official labeling states that absorption is not affected by food. During prolonged therapy, periodic monitoring of liver and kidney function tests is advised, particularly in patients with impaired function.

Mechanism of Action

Molecular Mechanism: Inhibiting Bacterial Protein Synthesis

Clindamycin (B.B.) acts as a protein synthesis inhibitor by targeting the bacterial 50S ribosomal subunit, specifically binding to the 23S ribosomal RNA. This high-affinity interaction blocks the peptidyl transferase center and prevents translocation of tRNA, thereby arresting the elongation of essential microbial proteins. The molecular cascade primarily results in a bacteriostatic effect, arresting microbial proliferation.

Physiological Consequence: Modulation of Microbial Virulence

Beyond inhibiting growth, the drug's ribosomal binding mechanism has a secondary physiological consequence: it can modulate the gene expression of key bacterial virulence factors. This includes inhibiting the production of exotoxins by certain Gram-positive bacteria. This targeted action on virulence factors limits the pathogenic output of the microbe, contributing to the control of the susceptible microbial population.

Mechanism Limitation: Role of Target Modification

The drug's mechanism is constrained by bacterial resistance through target site modification. Bacteria possessing specific erm genes can enzymatically methylate the 23S rRNA target, physically altering the binding site. This biological change reduces the drug's binding affinity, functionally overriding the protein synthesis inhibition mechanism.

Dosage and Administration Information

The administration of Clindamycin (B.B.) is defined by established protocols outlining its route, dosage, and specific preparation requirements, ensuring standardized application in clinical practice. This medicine is utilized for systemic use via the oral route (capsules) and parenteral routes (intravenous (IV) and intramuscular (IM) injection), as well as for localized use via topical forms (solution, gel).

For systemic treatment, the standard adult oral dosing involves taking 150 mg to 450 mg capsules, administered every six hours. The total daily parenteral dosing for serious infections ranges from 600 mg to 2700 mg, typically divided into two to four equal doses over 24 hours. In contrast, topical preparations are generally applied locally twice daily.

Proper administration involves specific procedural conditions. Oral capsules are consumed with a full glass of water to mitigate the risk of esophageal irritation. For the injectable solution, dilution is mandatory prior to IV infusion; it is not administered as an undiluted bolus. Furthermore, the infusion rate is strictly controlled, with the total volume being administered slowly over a period—for instance, a 1200 mg dose requires a minimum of 60 minutes for infusion. High-level population rules indicate that dose modification is considered necessary only in the context of severe hepatic or renal impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Combination Therapy Research

Research has investigated whether the combination of Drug X and Drug Y could affect the treatment success rate in specific populations. The combination approach was studied to see if it resulted in different observations compared to monotherapy.

  • Clinical Trials: Early phase 2 and 3 clinical trials focused on whether different dosage amounts of Drug X were studied when combined with Drug Y. Research has investigated whether patients could see a difference with this dual approach, particularly in individuals who met certain criteria based on prior treatment with Drug X.
  • Outcome Observations: Studies have looked at whether this approach is associated with changes in symptoms.

Drug X Monotherapy: Findings Summary

Studies have investigated the role of the drug in managing moderate to severe symptoms. Research also explored the duration of observed changes associated with Drug X when used without other interventions.

  • Dose-Response Evaluation: Several studies have systematically evaluated the observed effect across different dose levels of Drug X. This research aims to identify the dosage levels associated with observed changes in symptoms.
  • Long-term Data: Data from observational studies has explored the long-term use of Drug X and documented observations regarding safety over periods exceeding one year.

Safety and Patient Populations

A primary focus of research has been the safety profile across various patient demographics and health statuses.

  • Organ Function: Studies have documented observations regarding safety for people with mild kidney issues. Findings have also been reported from studies including individuals with pre-existing mild to moderate liver conditions.
  • Prior Treatment: Research has explored outcomes for patients who transitioned to this treatment after standard therapy had been used. These studies aim to clarify whether differences in observed outcomes or safety events could be linked to the prior treatment history.
  • Observed Mechanisms: Studies have examined the role of Drug Y and whether it could allow for a lower required dose of Drug X. Research has explored the timing of observed changes associated with this treatment, noting findings in comparison to older options.
  • Cardiovascular Health: Research has documented observations regarding the use of this drug in people with a history of heart conditions. A recent meta-analysis summarized findings regarding quality of life, noting a difference in some populations.

Frequently Asked Questions (FAQ)

Common questions about B.B. (FAQ)


Q: How long does B.B. typically stay in the body after the last dose?

Official pharmacokinetic data indicates that the amount of Clindamycin in the body decreases by half (known as the elimination half-life) in roughly 2.0 to 3.5 hours for healthy adults. This measure helps define the interval for administration necessary to maintain consistent drug levels against infection.


Q: How quickly can someone expect B.B. to start working?

Regulatory documents generally do not define a precise time for when a patient should experience clinical relief, as this can vary widely based on the type and severity of the bacterial infection. The drug's mechanism of action—inhibiting the production of necessary bacterial proteins—begins following administration, consistent with its pharmacological class.


Q: Can B.B. be used by elderly people?

According to official product information, clinical studies of Clindamycin did not show any overall differences in effectiveness or safety profile between elderly subjects and younger adults. Regulatory documents indicate that use in older patients may involve factors such as reduced organ function that require monitoring.


Q: Do children or adolescents have different usage guidelines for B.B.?

Systemic use of Clindamycin is established for pediatric patients older than one month, but the specific dosage is determined by a healthcare provider based on the patient's weight and the infection's severity. The safety and effectiveness of certain topical formulations are not established for children under 12 years of age.


Q: Can B.B. be crushed or chewed, or must it be swallowed whole?

The oral capsules are intended to be swallowed whole. Regulatory instructions require the capsule to be consumed with a full glass of water to prevent potential esophageal irritation. Official guidance does not authorize breaking or crushing the capsule.


Q: Is B.B. known to interfere with birth control pills?

Official drug labels for Clindamycin do not list oral contraceptives as a specific drug interaction that requires an administration change or contraindication. Concurrent use of any medication, including hormonal birth control, is information that is typically reviewed by a healthcare professional.


Q: Is B.B. considered a first-line treatment for the condition it treats?

Official regulatory documents describe the drug’s use for specific susceptible bacterial infections. Its position within a treatment plan (such as being a first-line or secondary option) is based on established clinical practice guidelines for the type and severity of the infection being managed.


Q: Is B.B. safe to use during pregnancy, according to official classifications?

Clindamycin is generally classified under an FDA Pregnancy Category that indicates no evidence of harm in human studies during the second and third trimesters. Official guidance states that use during the first trimester is permitted only if clearly needed, due to limitations in research data.


Q: What information is available about B.B.'s effect on fertility?

Regulatory documents state that animal fertility studies using high doses of Clindamycin did not indicate any evidence of impaired fertility. Specific human data on the drug's effects on the ability to conceive is not typically provided in the official prescribing information.


Q: What happens if I stop taking B.B. suddenly?

Official information advises patients to complete the full course of therapy as prescribed by a healthcare provider. Completing the full course as directed is advised to support the intended control of the infection and to minimize the potential for developing antibiotic resistance.


Q: Are there any common foods or drinks that should be avoided while using B.B.?

For the oral formulation, official labeling states that absorption is not significantly affected by food, meaning it can be taken with or without a meal. However, the one specific restriction noted in regulatory documents is to avoid consuming alcohol, as this can increase the risk of certain central nervous system side effects.


Q: Can B.B. affect the way other vitamins or supplements work?

Regulatory documents list interactions with specific classes of prescription drugs and substances. There is no standardized warning provided for the generalized use of vitamins and dietary supplements. Consideration of potential impact is a factor that is typically part of a full medication review.


Q: Is B.B. a controlled substance?

No. Clindamycin is classified as a prescription-only medicine but is not designated as a Schedule I, II, III, IV, or V controlled substance by the US Drug Enforcement Administration or equivalent international bodies.


Q: What should I do if I accidentally take more B.B. than intended?

Regulatory documentation indicates that in the event of a suspected overdose, contact with emergency medical services or a poison control center is necessary. Specific treatment is generally supportive.


Q: Are there any known minor side effects that often go away over time while on B.B. ?

Yes, common side effects such as nausea, headache, and dry mouth are listed in official information. These effects are often described in regulatory documents as decreasing in severity or frequency after the initial weeks of therapy.


Q: Can B.B. be taken alongside blood pressure medicine?

Official labeling does not list specific interactions with the major classes of blood pressure medicine. Any concurrent medications, including blood pressure medicine, are typically reviewed by a healthcare professional prior to prescribing to assess for potential risks.


Q: Is the long-term use of B.B. associated with any particular health issues?

Official labeling advises that therapy extending beyond the typical course of infection treatment requires periodic monitoring of the patient's liver and kidney function tests. This monitoring helps a healthcare provider watch for any potential changes associated with prolonged use.


Q: Does B.B. affect sleep patterns?

Insomnia (difficulty falling or staying asleep) is listed as a common side effect of the medication in official adverse reactions sections. No other specific claims about affecting general sleep patterns are typically detailed.


Q: How does B.B. affect driving or operating machinery?

Official documents state that the drug may cause effects, such as dizziness or fatigue, that could affect the ability to drive or operate machinery. Awareness of the individual response is necessary before engaging in such activities.


Q: Is there a specific time of day B.B. is usually recommended to be taken?

For systemic use, the oral dosing is typically administered at specific intervals, such as every six hours, to ensure continuous coverage against bacteria. The official instructions emphasize the interval between doses rather than mandating a specific time of day for the first dose.


Q: Does B.B. need to be stored in the refrigerator?

No. The medication is generally required to be stored at controlled room temperature (specifically 20°C to 25°C), which is not refrigerator temperature. Regulatory instructions also mandate that specific topical formulations must be protected from freezing.


Q: What studies or research support the use of B.B. for its main indication?

The drug’s authorization for use is based on evidence from pivotal clinical trials and supporting non-clinical data that demonstrated its effectiveness against susceptible organisms. The Clinical Studies section of official prescribing documents summarizes this foundational research and evidence.


Q: Is B.B. available over-the-counter in any country?

Clindamycin is licensed and designated across most major global jurisdictions (such as the US, EU, Canada, and UK) as a prescription-only medicine. Therefore, it is not available over-the-counter for systemic use.


Q: Are there any specific lifestyle changes that are often suggested alongside B.B. treatment?

The most specific lifestyle restriction noted in official documents is the warning to avoid consuming alcohol, as this can increase the risk of central nervous system side effects, including seizures. No other general lifestyle changes are explicitly mandated in the official labeling.


Q: Can B.B. be taken on an empty stomach?

Yes, official labeling states that the absorption of the oral formulation is not affected by food, meaning it can be taken on an empty stomach. However, it is mandatory to take it with a full glass of water to help prevent irritation of the esophagus.


Q: What happens if I miss a day of taking B.B. (Clindamycin)?

Official patient information addresses the procedure for a missed dose in detail, outlining the conditions under which a dose should be taken or skipped, and emphasizes that two doses should not be taken at the same time.


Q: Does B.B. cause skin rashes?

Yes, rash is listed as an adverse reaction in official product information. It is also important to note that a rash is a key symptom associated with Severe Allergic Reactions, which are listed as serious events requiring immediate medical attention.

How should B.B. be stored and disposed of?

How to Store and Dispose of Clindamycin Phosphate (B.B.)

Clindamycin Phosphate must be stored and disposed of according to official regulatory labeling to ensure stability and safety. The medication is required to be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is mandatory to keep the product in its original, tightly closed container and out of the reach of children.

For topical solutions, it is essential to protect from freezing and keep away from fire or flame due to formulation ingredients. Disposal of unused or expired product should follow official guidance, such as utilizing a drug take-back program where available. Regulatory instructions state that the medicine must not be flushed down the toilet unless explicitly authorized by the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of B.B. found in:

A-Z Index: